Clinical trials: Lymphatic System Neoplasm
Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Phase 3, 2-arm, randomized, open label trial. Patients will be randomized to receive bosutinib or imatinib for the duration of the study.
- Trial name
- NCT02130557
- Testing
- Bosutinib, Imatinib
- Where
- 189 sites in United States, Australia and 24 more
- Volunteers
- 536 people
- Sponsor
- Pfizer
Chemotherapy-Induced Thrombocytopenia, Hodgkin's Lymphoma
A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma
The purpose of this study is to identify a well-tolerated, effective dose and schedule of AMG 531 for the treatment of Chemotherapy Induced Thrombocytopenia (CIT) in subjects with lymphoma receiving multi-cycle chemotherapy.
- Conditions
- Chemotherapy-Induced Thrombocytopenia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Cancer
- Trial name
- NCT00283439
- Testing
- AMG 531
- Volunteers
- 39 people
- Sponsor
- Amgen
Lymphoma, Follicular
A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
This study will evaluate the safety, efficacy, pharmacokinetics and immunogenicity of induction treatment consisting of atezolizumab in combination with obinutuzumab plus lenalidomide in patients with relapsed or refractory…
- Trial name
- NCT02631577
- Testing
- Atezolizumab (MPDL3280A) [TECENTRIQ], Lenalidomide, Obinutuzumab
- Where
- 16 sites in United States, France
- Volunteers
- 38 people
- Sponsor
- Hoffmann-La Roche
Neoplasms, Lymphoma
A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System
This study is in 2 parts. The main aims of the 1st part of the study are to check if people with advanced solid tumors or cancers in the immune system (lymphomas) have side effects from TAK-981, and to check how much TAK-981 they…
- Conditions
- Neoplasms, Lymphoma, Hematologic Neoplasms
- Trial name
- NCT03648372
- Testing
- TAK-981
- Where
- 8 sites in United States
- Volunteers
- 109 people
- Sponsor
- Takeda
MDS, AML
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
The purpose of this study is to evaluate three things. The first being whether azacitidine is absorbed in the body at the same rate or proportion for different concentrations.
- Conditions
- MDS, AML, Solid Tumors, Multiple Myeloma
- Trial name
- RENAL (NCT00652626)
- Testing
- azacitidine
- Where
- 11 sites in United States
- Volunteers
- 31 people
- Sponsor
- Celgene
Non-Hodgkin Lymphoma
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)
This is an open-label, multicenter study to characterize the safety and efficacy of the human anti-CD19 antibody MOR00208 in adult patients with relapsed/refractory non-Hodgkin's lymphoma (NHL) who have received at least 1 prior…
- Trial name
- NCT01685008
- Testing
- MOR00208 (formerly Xmab 5574)
- Where
- 22 sites in United States, Belgium and 5 more
- Volunteers
- 92 people
- Sponsor
- MorphoSys AG
Lymphoma, Large B-Cell, Diffuse
18F-FDG PET Radiomics of Diffuse Large B-cell Lymphoma
This study aims to investigate the prognostic value of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) radiomics in diffuse large B-cell lymphoma (DLBCL) and its additional value to the International…
- Trial name
- NCT04317313
- Testing
- FDG PET radiomic feature evaluation
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission
Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes
This randomized phase II trial studies how well donor umbilical cord blood transplant with or without ex-vivo expanded cord blood progenitor cells works in treating patients with acute myeloid leukemia, acute lymphoblastic…
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Myelogenous Leukemia
- Trial name
- NCT01690520
- Testing
- Cyclophosphamide, Cyclosporine, Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion
- Where
- 8 sites in United States
- Volunteers
- 163 people
- Sponsor
- Nohla Therapeutics, Inc.
T-cell Lymphomas, Relapsed or Refractory
Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
This is an open label phase Ib/IIa study of patients with relapsed/refractory B- and T-cell lymphomas who are treated with carfilzomib, lenalidomide and romidepsin.
- Trial name
- NCT02341014
- Testing
- Carfilzomib, Romidepsin, Lenalidomide
- Where
- 6 sites in United States
- Volunteers
- 27 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diffuse Large B-Cell Lymphoma
Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)
Evaluation of impact of metformin on 2 year progression-free survival (PFS) rate in subjects with previously untreated DLBCL when added to standard induction therapy. (R-CHOP)
- Trial name
- DLBCL (NCT02531308)
- Testing
- Metformin, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Rush University Medical Center
Indolent Non-Hodgkin's Lymphomas
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
The primary objective of this study is to evaluate the effect of the addition of idelalisib to rituximab on progression-free survival (PFS) in adults with previously treated indolent non-Hodgkin lymphoma (iNHL).
- Trial name
- Yosemite (NCT01732913)
- Testing
- Rituximab, Idelalisib
- Where
- 103 sites in United States, Australia and 17 more
- Volunteers
- 295 people
- Sponsor
- Gilead Sciences
Sezary Syndrome, Pruritus
Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome
The purpose of this randomized, double-blinded, placebo-controlled study is to test the hypothesis that administration of aprepitant will decrease the severity of pruritus in patients with Sèzary Syndrome.
- Trial name
- NCT01625455
- Testing
- Aprepitant
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Vanderbilt University Medical Center
Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
This is a phase-II study to evaluate the efficacy of a salvage regimen in children with relapsed T-cell ALL or lymphoma. Peg-asparaginase, mitoxantrone, intrathecal triples (IT) (intrathecal…
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's, Leukemia, T-Cell, Leukemia, B-Cell
- Trial name
- NCT02518750
- Testing
- Dexamethasone, Panobinostat, Liposomal vincristine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- St. Jude Children's Research Hospital
Indolent Plasma Cell Myeloma, Plasma Cell Myeloma
Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma
This partially randomized phase I/II trial studies the side effects and best dose of anakinra when given together with lenalidomide and dexamethasone in treating patients with early stage multiple myeloma.
- Conditions
- Indolent Plasma Cell Myeloma, Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
- Trial name
- NCT02492750
- Testing
- Anakinra, Dexamethasone, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Mayo Clinic
Multiple Myeloma and Plasma Cell Neoplasm
Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma
RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about T cells and plan better treatment for multiple myeloma.
- Trial name
- NCT00897910
- Testing
- flow cytometry, immunoenzyme technique, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha
During the Core Phase of the study, participants received STI571 at a dose of 400 milligrams (mg) daily for up to 12 months. Participants completing 12 months of therapy were eligible to continue treatment in the Extension Phase…
- Trial name
- NCT00171223
- Testing
- STI571
- Where
- 28 sites in United States, France and 4 more
- Volunteers
- 532 people
- Sponsor
- Novartis Pharmaceuticals
Mantle Cell Lymphoma
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
The primary objective of this study was to evaluate the efficacy of ibrutinib in participants with relapsed or refractory MCL. The secondary objective was to evaluate the safety of a fixed daily dosing regimen (560 mg daily) of…
- Trial name
- PCYC-1104-CA (NCT01236391)
- Testing
- PCI-32765
- Where
- 18 sites in United States, Germany and 2 more
- Volunteers
- 115 people
- Sponsor
- Pharmacyclics LLC.
Thymoma, Thymic Carcinoma
Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage
Background: Cisplatin-containing chemotherapy is the standard treatment for advanced tumors of the thymus that cannot be removed surgically.
- Trial name
- NCT00589290
- Testing
- Belinostat (PDX101)
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Non Hodgkin's Lymphoma
Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma
Lenalidomide has been shown to have single agent activity in indolent Non-Hodgkin's Lymphoma. It is approved for the treatment of multiple myeloma and myelodysplastic syndrome.
- Trial name
- NCT01316523
- Testing
- Rituximab, Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of California, Davis
Thalassemia
Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO
Patients have severe beta-thalassemia or one of the thalassemia variants. Thalassemia is a hereditary disease in which the bone marrow produces abnormal red blood cells that have a shorter life span than normal red blood cells.
- Trial name
- THALLO (NCT00578292)
- Testing
- Busulfan, Fludarabine, Campath 1H
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Baylor College of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.